JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 23.3 Billion JPY | 2.19% |
| 2022 | 22.8 Billion JPY | 25.97% |
| 2021 | 18.1 Billion JPY | 0.0% |
| 2020 | 18.1 Billion JPY | 106.69% |
| 2019 | 8.75 Billion JPY | 52.8% |
| 2018 | 5.73 Billion JPY | -1.26% |
| 2017 | 5.8 Billion JPY | 19.95% |
| 2016 | 4.83 Billion JPY | 51.51% |
| 2015 | 3.19 Billion JPY | -12.21% |
| 2014 | 3.63 Billion JPY | -14.59% |
| 2013 | 4.25 Billion JPY | 2.58% |
| 2012 | 4.15 Billion JPY | 2.79% |
| 2011 | 4.03 Billion JPY | -1.29% |
| 2010 | 4.09 Billion JPY | -20.65% |
| 2009 | 5.15 Billion JPY | 1.45% |
| 2008 | 5.08 Billion JPY | 0.14% |
| 2007 | 5.07 Billion JPY | -2.06% |
| 2006 | 5.18 Billion JPY | 22.02% |
| 2005 | 4.24 Billion JPY | -34.11% |
| 2004 | 6.44 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 28.22 Billion JPY | 2.19% |
| 2024 Q2 | 28.41 Billion JPY | 0.0% |
| 2023 Q1 | 23.3 Billion JPY | 2.19% |
| 2023 Q3 | 23.3 Billion JPY | 0.0% |
| 2023 Q2 | 23.3 Billion JPY | 0.0% |
| 2023 Q4 | 23.3 Billion JPY | 0.0% |
| 2023 FY | 23.3 Billion JPY | 2.19% |
| 2022 Q2 | 18.1 Billion JPY | 0.0% |
| 2022 Q4 | 22.8 Billion JPY | 25.97% |
| 2022 FY | 22.8 Billion JPY | 25.97% |
| 2022 Q1 | 18.1 Billion JPY | 0.0% |
| 2022 Q3 | 18.1 Billion JPY | 0.0% |
| 2021 Q3 | 18.1 Billion JPY | 0.0% |
| 2021 Q4 | 18.1 Billion JPY | 0.0% |
| 2021 FY | 18.1 Billion JPY | 0.0% |
| 2021 Q1 | 18.1 Billion JPY | 0.0% |
| 2021 Q2 | 18.1 Billion JPY | 0.0% |
| 2020 Q1 | 17.4 Billion JPY | 98.7% |
| 2020 Q4 | 18.1 Billion JPY | 0.0% |
| 2020 FY | 18.1 Billion JPY | 106.69% |
| 2020 Q2 | 18.1 Billion JPY | 4.02% |
| 2020 Q3 | 18.1 Billion JPY | 0.0% |
| 2019 Q1 | 5.48 Billion JPY | -4.38% |
| 2019 FY | 8.75 Billion JPY | 52.8% |
| 2019 Q3 | 8.68 Billion JPY | 0.0% |
| 2019 Q4 | 8.75 Billion JPY | 0.89% |
| 2019 Q2 | 8.68 Billion JPY | 58.39% |
| 2018 Q1 | 5.38 Billion JPY | -7.24% |
| 2018 FY | 5.73 Billion JPY | -1.26% |
| 2018 Q4 | 5.73 Billion JPY | 4.58% |
| 2018 Q3 | 5.48 Billion JPY | 0.0% |
| 2018 Q2 | 5.48 Billion JPY | 1.78% |
| 2017 Q1 | 4.23 Billion JPY | -12.44% |
| 2017 FY | 5.8 Billion JPY | 19.95% |
| 2017 Q2 | 5.79 Billion JPY | 36.65% |
| 2017 Q4 | 5.8 Billion JPY | -23.64% |
| 2017 Q3 | 7.6 Billion JPY | 31.28% |
| 2016 Q4 | 4.83 Billion JPY | 11.06% |
| 2016 FY | 4.83 Billion JPY | 51.51% |
| 2016 Q3 | 4.35 Billion JPY | -0.0% |
| 2016 Q2 | 4.35 Billion JPY | -1.47% |
| 2016 Q1 | 4.42 Billion JPY | 38.46% |
| 2015 Q3 | 2.48 Billion JPY | -2.94% |
| 2015 Q2 | 2.55 Billion JPY | 0.27% |
| 2015 Q1 | 2.55 Billion JPY | -29.9% |
| 2015 Q4 | 3.19 Billion JPY | 28.67% |
| 2015 FY | 3.19 Billion JPY | -12.21% |
| 2014 FY | 3.63 Billion JPY | -14.59% |
| 2014 Q4 | 3.63 Billion JPY | 30.73% |
| 2014 Q3 | 2.78 Billion JPY | -4.01% |
| 2014 Q2 | 2.89 Billion JPY | -3.86% |
| 2014 Q1 | 3.01 Billion JPY | -29.21% |
| 2013 FY | 4.25 Billion JPY | 2.58% |
| 2013 Q1 | 2.68 Billion JPY | -35.32% |
| 2013 Q2 | 2.83 Billion JPY | 5.4% |
| 2013 Q3 | 2.66 Billion JPY | -5.82% |
| 2013 Q4 | 4.25 Billion JPY | 59.75% |
| 2012 Q2 | 2.99 Billion JPY | 32.88% |
| 2012 Q4 | 4.15 Billion JPY | 29.94% |
| 2012 FY | 4.15 Billion JPY | 2.79% |
| 2012 Q1 | 2.25 Billion JPY | -44.2% |
| 2012 Q3 | 3.19 Billion JPY | 6.7% |
| 2011 FY | 4.03 Billion JPY | -1.29% |
| 2011 Q4 | 4.03 Billion JPY | 55.73% |
| 2011 Q3 | 2.59 Billion JPY | -10.64% |
| 2011 Q2 | 2.9 Billion JPY | 25.45% |
| 2011 Q1 | 2.31 Billion JPY | -43.45% |
| 2010 Q3 | 2.43 Billion JPY | 6.33% |
| 2010 Q4 | 4.09 Billion JPY | 68.12% |
| 2010 FY | 4.09 Billion JPY | -20.65% |
| 2010 Q1 | 2.35 Billion JPY | -54.39% |
| 2010 Q2 | 2.28 Billion JPY | -2.69% |
| 2009 FY | 5.15 Billion JPY | 1.45% |
| 2009 Q2 | 4.61 Billion JPY | 0.0% |
| 2009 Q4 | 5.15 Billion JPY | 12.87% |
| 2009 Q3 | 4.56 Billion JPY | -0.91% |
| 2008 Q3 | 4.41 Billion JPY | 0.0% |
| 2008 Q4 | 5.08 Billion JPY | 15.12% |
| 2008 FY | 5.08 Billion JPY | 0.14% |
| 2007 FY | 5.07 Billion JPY | -2.06% |
| 2006 FY | 5.18 Billion JPY | 22.02% |
| 2005 FY | 4.24 Billion JPY | -34.11% |
| 2004 FY | 6.44 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 24.24 Billion JPY | 3.906% |
| Astellas Pharma Inc. | 1005.71 Billion JPY | 97.683% |
| Chugai Pharmaceutical Co., Ltd. | 13.45 Billion JPY | -73.17% |
| Ono Pharmaceutical Co., Ltd. | 8.86 Billion JPY | -162.92% |
| Santen Pharmaceutical Co., Ltd. | 35.15 Billion JPY | 33.728% |
| Daiichi Sankyo Company, Limited | 156 Billion JPY | 85.064% |
| Otsuka Holdings Co., Ltd. | 214.18 Billion JPY | 89.122% |
| Perseus Proteomics Inc. | - JPY | -Infinity% |